Cowen analyst Charles Rhyee raised the price target on McKesson (NYSE: MCK) to $174.00 (from $170.00) while maintaining an Outperform rating.

The analyst commented, "Given strong underlying fundamentals in U.S. Pharma & Specialty, as well as effective execution, we think there's potential for upside to FY20 segment guidance and sets up MCK well for FY21. We've also updated our model to reflect MCK's updated FY20 guidance assumptions. As such, we raise our estimates as well as our PT."